To examine combination therapies that improve Tvax efficacy in established tumors, we combined TvaxOVA/mtIL-12/GM-CSF with long-acting albumin-fused IL-2, an anti–PD-1 antibody, and a tumor-reactive anti-TRP1 antibody in the B16-OVA model, initiating vaccination on day 11 after implantation when tumors were palpable. This evidence concerns the gene PDCD1 and neoplasm.